CD38


Also found in: Acronyms, Wikipedia.

CD38

a transmembrane protein present on macrophages, dendritic cells, and activated cells of the natural killer, B-cell and T-cell lines that can facilitate B-cell adhesion.
References in periodicals archive ?
CD38 was initially identified as a lymphocyte-specific antigen [7] and was later found to be a major NADase in mammalian tissues [8].
hAM-MSC caused a reduction in the expression of Tcell activation markers, CD38 and HLA-DR.
As shown previously (Figure 3(a)), about half (52 [+ or -] 5%, n = 8) of the expanded cells were positive for CD38 expression and less than 10% were [CD138.sup.+] (6 [+ or -] 3%, n = 8)at D0.
Immunophenotyping of bone marrow aspirate was performed using CD45, CD19, CD56, and CD38 (a limited panel of markers was used due to financial constraints).
The understanding of CD38 expression has largely been driven by its use as a marker for cellular activation in estimating disease prognosis in patients with HIV-1 infection [1,3-6,13-14] and more recently in chronic lymphocytic leukaemia (CLL) [37-39].
Giorgi, Quantitation of CD38 Expression Using QuantiBRITE[TM] Beads, Cytometry 33, 206-212 (1998).
Airway myocytes from CD38 knockout (CD38KO) mice exhibit attenuated intracellular [Ca.sup.2+] ([[[Ca.sup.2+]].sub.i]) responses to agonists [2] and methacholine-induced airway responsiveness in the CD38KO mice is lower than in wild-type (WT) mice.
cADPR and CD38 antibody were purchased from Santa Cruz Biotechnology (Dallas, TX, USA).
Immunophenotypic evaluation by flow cytometry of fchain-associated protein kinase 70 (ZAP-70) and CD38 may be used to predict the clinical course of CLL and is frequently part of standard diagnostic panels.
The first study to date in HIV used CD38 and HLA-DR as the activation markers which were conducted on HIV positive patients who were on antiretroviral treatment [15].
We also built upon our already successful relationship with Janssen with the signing of an agreement to collaborate exclusively on the next-generation CD38 antibody product candidate, HexaBody-CD38.
Daratumumab is a first-in-class5 biologic targeting CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage.